Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Date:11/6/2012

Equity  Accounts payable and accrued liabilities

$   9,431$   9,574  Total deferred revenues

47,05044,682  Total derivative liabilities

15,5031,617  Total note payable to Deerfield

014,698  Total lease financing obligations & other long-term liabilities

74,91075,996  Total stockholders' equity

117,26610,562Total liabilities & stockholders' equity

$ 264,160$ 157,1291 The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date. Contact: Arena Pharmaceuticals, Inc.

 Media Contact: Russo PartnersCindy McGee, Vice PresidentDavid Schull, PresidentInvestor Relations & Alliance Management

david.schull@russopartnersllc.comcmcgee@arenapharm.com 

858.717.2310858.453.7200, ext. 1479  


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
2. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
4. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
6. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
7. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
8. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
9. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
10. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Perrigo Company plc, a public limited company ... (the " Company "), today announced that it is offering ... new 1.30% Senior Notes due 2016 (the " 2016 Exchange ... 2018 (the " 2018 Exchange Notes "), $800,000,000 of its ... Notes ") and $400,00,000 of its new 5.30% Senior Notes ...
(Date:9/2/2014)... AUSTIN, Texas , Sept. 2, 2014 /PRNewswire/ ... Phase III study being conducted in the US ... a True Human™ monoclonal antibody therapy, is being ... is further complicated with cachexia. The primary endpoint ... in Xilonix treated patients to a control population ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Work Status and,Productivity, WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ ... (DDW), from,long-term extensions of the ACT trials (Active ... moderately to severely active,ulcerative colitis (UC) who had ... the trials maintained,improvement in their clinical symptoms for ...
... WIRE)--May 23, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: ... and commercializing small,molecule drugs to treat severe ... data from the Phase 2b clinical,trial in ... drug,candidate, STA-4783, will be presented at the ...
Cached Medicine Technology:Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
(Date:9/3/2014)... Pwnie Express today announced the release ... Plug, the R3, an inconspicuous pentesting device whose drop ... remote locations at a fraction of the cost of ... the only company to assess wired and wireless network ... a next-generation penetration testing device in a portable, shippable, ...
(Date:9/3/2014)... 03, 2014 Morris Psychological ... free screenings for depression on October 9, 2014 ... Court). More than 1,000 organizations nationwide will be ... colleges and military installations. After completing a screening, ... and agencies that can offer further evaluation and ...
(Date:9/2/2014)... 03, 2014 Autumn is well ... to celebrate the new season with worldwide people. ... and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, ... of 2014. , Since 2002 HostGator has ... and the company’s reputation for reliability remains with ...
(Date:9/2/2014)... Fla. (PRWEB) September 02, 2014 ... join together in Tampa Bay from September 4-6 ... annual Scientific Symposium and FARA Energy Ball Gala. ... USF Ataxia Research Center in their pursuit of ... affected by the progressive neuromuscular disease Friedreich’s ataxia ...
(Date:9/2/2014)... 03, 2014 UWDress.com, an experienced supplier ... added a lot of fashionable bridesmaid dresses ... company has launched a special offer to celebrate the ... from 20 to 60 percent off. , The ... announce our new fashionable bridesmaid dresses for consumers from ...
Breaking Medicine News(10 mins):Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 3Health News:Elegant Bridesmaid Dresses For 2014, Latest Designs From UWDress.com 2
... DENVER, July 28 ThinIdentity Corporation, a ... announced that Alegent Health is moving forward with plans ... The first installation is located at its Mercy Hospital ... has over 1,000 caregivers using the ThinIdentity solution to ...
... , WILMINGTON, Delaware, July 28 ... - 2014), published by,MarketsandMarkets ( http://www.marketsandmarkets.com ), the total drug-device,combination ... out of,which the U.S. market will account for nearly 30.9% ... a CAGR of 11.8% from 2009 to 2014. , ...
... ... CompactRIO embedded real-time platform at the 15th annual NIWeek, opening Aug. 4 at the ... and exhibition hosted by National Instruments. , ... Irvine, CA (PRWEB) July 27, 2009 -- MoviMED ( www.movimed.com ...
... ... find medical assistant training at All Allied Health Schools. , ... Seattle, Wash. (PRWEB) July 28, 2009 -- With current unemployment ... In 2006, the Bureau of Labor Statistics predicted 35 percent growth in medical assistant ...
... ... centers and healthcare facilities acquire financing for new and professionally refurbished medical equipment. , ... (Vocus) July 28, 2009 -- With ... to purchase medical equipment . DRE, Inc. — named a Company of the Year ...
... , ... Cleanroom wipers manufactured by Teknipure offer innovative ... to finish in one facility enabling maximum quality control and are ... Basis Weight, Sorbency, Liquid Particle Count, Non-Volatile Residue levels, Ionic Extractable ...
Cached Medicine News:Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3Health News:Students Connect with Stable Careers Through Updated Medical Assistant Career Resources on All Allied Health Schools 2Health News:Students Connect with Stable Careers Through Updated Medical Assistant Career Resources on All Allied Health Schools 3Health News:Financing Available for Healthcare Equipment from DRE Medical Equipment 2Health News:Financing Available for Healthcare Equipment from DRE Medical Equipment 3Health News:Teknipure Cleanroom Wipers Offer Innovative Solutions for Contamination Control Engineers 2
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Similar in construction to the E2002 Utrata Capsulorhexis Forceps with jaw set to open only 3 mm. Flat handle with dull finish....
Medicine Products: